Neogenomics (NEO) Cost of Revenue (2010 - 2026)

Neogenomics (NEO) has reported Cost of Revenue for 17 consecutive years, with $105.8 million the latest figure, recorded in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $105.8 million, up 366.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $260.7 million (down 49.46% YoY), and the FY2025 annual result was $92.0 million, down 75.16% from the prior year.
• Cost of Revenue was $105.8 million for Q1 2026 at Neogenomics, up from $23.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $308.2 million in Q4 2024 and troughed at -$188.2 million in Q4 2023.
• Average Cost of Revenue over 5 years is $55.0 million, with a median of $24.1 million recorded in 2025.
• Year-over-year, Cost of Revenue sank 1198.08% in 2023 and soared 458.28% in 2024.
• Over 5 years, Cost of Revenue stood at $17.1 million in 2022, then tumbled by 1198.08% to -$188.2 million in 2023, then surged by 263.71% to $308.2 million in 2024, then sank by 92.39% to $23.4 million in 2025, then soared by 351.34% to $105.8 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $105.8 million in Q1 2026, $23.4 million in Q4 2025, and $107.4 million in Q3 2025.